Literature DB >> 23987235

Impact of hematopoietic cyclooxygenase-1 deficiency on obesity-linked adipose tissue inflammation and metabolic disorders in mice.

Viswanathan Saraswathi1, Christopher J Ramnanan, Anson W Wilks, Cyrus V Desouza, Amy A Eller, Ganesan Murali, Ramesh Ramalingam, Ginger L Milne, Katie C Coate, Dale S Edgerton.   

Abstract

OBJECTIVE: Adipose tissue (AT)-specific inflammation is considered to mediate the pathological consequences of obesity and macrophages are known to activate inflammatory pathways in obese AT. Because cyclooxygenases play a central role in regulating the inflammatory processes, we sought to determine the role of hematopoietic cyclooxygenase-1 (COX-1) in modulating AT inflammation in obesity. MATERIALS/
METHODS: Bone marrow transplantation was performed to delete COX-1 in hematopoietic cells. Briefly, female wild type (wt) mice were lethally irradiated and injected with bone marrow (BM) cells collected from wild type (COX-1+/+) or COX-1 knock-out (COX-1-/-) donor mice. The mice were fed a high fat diet for 16 weeks.
RESULTS: The mice that received COX-1-/- bone marrow (BM-COX-1-/-) exhibited a significant increase in fasting glucose, total cholesterol and triglycerides in the circulation compared to control (BM-COX-1+/+) mice. Markers of AT-inflammation were increased and were associated with increased leptin and decreased adiponectin in plasma. Hepatic inflammation was reduced with a concomitant reduction in TXB2 levels. The hepatic mRNA expression of genes involved in lipogenesis and lipid transport was increased while expression of genes involved in regulating hepatic glucose output was reduced in BM-COX-1-/- mice. Finally, renal inflammation and markers of renal glucose release were increased in BM-COX-1-/- mice.
CONCLUSION: Hematopoietic COX-1 deletion results in impairments in metabolic homeostasis which may be partly due to increased AT inflammation and dysregulated adipokine profile. An increase in renal glucose release and hepatic lipogenesis/lipid transport may also play a role, at least in part, in mediating hyperglycemia and dyslipidemia, respectively. Published by Elsevier Inc.

Entities:  

Keywords:  3-hydroxy-3-methyl-glutaryl-CoA reductase; 4′,6-diamidino-2-phenylindole;F4/80, murine homologue of EGF-like module-containing mucin-like hormone receptor-like 1; AMPK; AT; BMT; CC chemokine receptor-2; CC chemokine receptor-5; CCR2; CCR5; CD68; COX; COX-1 knock-out; COX-1+/+; COX-1−/−; CPT-1; DAPI; Dyslipidemia; Eicosanoids; FASN; FBP-1; G6PC; GAPDH; GC/MS; GSK; Glut-4; HMGCR; HOMA-IR; Hyperglycemia; IL; IR-β; L-FABP; LDLR; MCP-1; MGL; MIP-1α; MMP-12; NMR; Obesity; PCK-1 and PEPCK; PCX; PG; SAA-3; SGLT-2; SVC; TLR4; TNFα; TX; adenosine monophosphate-activated protein kinase; adipose tissue; apoE; apolipoprotein E; bone marrow transplantation; carnitine palmitoyl transferase-1; cluster of differentiation 68; cyclooxygenase; fatty acid synthase; fructose 1,6 bisphosphatase; gas chromatography/mass spectrometry; glucose transporter-4; glucose-6-phosphatase; glyceraldehyde 3 phosphate dehydrogenase; glycogen synthase kinase; homeostasis model assessment of insulin resistance; interleukin; liver fatty acid binding protein; low density lipoprotein receptor; macrophage galactose type lectin; macrophage inflammatory protein-1α; matrix metalloproteinase-12; monocyte chemoattractant protein; nuclear magnetic resonance; phospho insulin receptor beta; phosphoenol pyruvate carboxykinase; prostaglandin; pyruvate carboxylase; serum amyloid A-3; sodium glucose cotransporter-2; stromal vascular cells; thromboxane; toll-like receptor 4; tumor necrosis factor alpha; wild type

Mesh:

Substances:

Year:  2013        PMID: 23987235      PMCID: PMC4845736          DOI: 10.1016/j.metabol.2013.07.007

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  60 in total

Review 1.  Cyclooxygenases: structural, cellular, and molecular biology.

Authors:  W L Smith; D L DeWitt; R M Garavito
Journal:  Annu Rev Biochem       Date:  2000       Impact factor: 23.643

Review 2.  Inflammatory resolution: new opportunities for drug discovery.

Authors:  Derek W Gilroy; Toby Lawrence; Mauro Perretti; Adriano G Rossi
Journal:  Nat Rev Drug Discov       Date:  2004-05       Impact factor: 84.694

3.  Dual, but not selective, COX-1 and COX-2 inhibitors, attenuate acetic acid-evoked bladder irritation in the anaesthetised female cat.

Authors:  Alexandra Wibberley; Gerald P McCafferty; Christopher Evans; Richard M Edwards; J Paul Hieble
Journal:  Br J Pharmacol       Date:  2006-05       Impact factor: 8.739

4.  Relationship between thromboxane/prostacyclin ratio and diabetic vascular complications.

Authors:  T Hishinuma; H Tsukamoto; K Suzuki; M Mizugaki
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2001-10       Impact factor: 4.006

Review 5.  Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications.

Authors:  Kenneth Cusi
Journal:  Gastroenterology       Date:  2012-02-08       Impact factor: 22.682

6.  Macrophage TNF-alpha contributes to insulin resistance and hepatic steatosis in diet-induced obesity.

Authors:  Bart M De Taeye; Tatiana Novitskaya; Owen P McGuinness; Linda Gleaves; Mousumi Medda; Joseph W Covington; Douglas E Vaughan
Journal:  Am J Physiol Endocrinol Metab       Date:  2007-06-19       Impact factor: 4.310

7.  Fish oil and indomethacin in combination potently reduce dyslipidemia and hepatic steatosis in LDLR(-/-) mice.

Authors:  Ganesan Murali; Ginger L Milne; Corey D Webb; Ann B Stewart; Ryan P McMillan; Brandon C Lyle; Matthew W Hulver; Viswanathan Saraswathi
Journal:  J Lipid Res       Date:  2012-07-29       Impact factor: 5.922

8.  Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration.

Authors:  R Langenbach; S G Morham; H F Tiano; C D Loftin; B I Ghanayem; P C Chulada; J F Mahler; C A Lee; E H Goulding; K D Kluckman; H S Kim; O Smithies
Journal:  Cell       Date:  1995-11-03       Impact factor: 41.582

9.  Toll-like receptor 4 deficiency promotes the alternative activation of adipose tissue macrophages.

Authors:  Jeb S Orr; Michael J Puglisi; Kate L J Ellacott; Carey N Lumeng; David H Wasserman; Alyssa H Hasty
Journal:  Diabetes       Date:  2012-06-29       Impact factor: 9.461

10.  CCR5 plays a critical role in obesity-induced adipose tissue inflammation and insulin resistance by regulating both macrophage recruitment and M1/M2 status.

Authors:  Hironori Kitade; Kazuki Sawamoto; Mayumi Nagashimada; Hiroshi Inoue; Yasuhiko Yamamoto; Yoshimichi Sai; Toshinari Takamura; Hiroshi Yamamoto; Ken-ichi Miyamoto; Henry N Ginsberg; Naofumi Mukaida; Shuichi Kaneko; Tsuguhito Ota
Journal:  Diabetes       Date:  2012-04-03       Impact factor: 9.461

View more
  9 in total

1.  Thromboxane synthase deficiency improves insulin action and attenuates adipose tissue fibrosis.

Authors:  Xia Lei; Qing Li; Susana Rodriguez; Stefanie Y Tan; Marcus M Seldin; John C McLenithan; Weiping Jia; G William Wong
Journal:  Am J Physiol Endocrinol Metab       Date:  2015-03-03       Impact factor: 4.310

2.  P2X7 Receptor Expression in Peripheral Blood Monocytes Is Correlated With Plasma C-Reactive Protein and Cytokine Levels in Patients With Type 2 Diabetes Mellitus: a Preliminary Report.

Authors:  Hong Wu; Yijun Nie; Huangui Xiong; Shuangmei Liu; Guilin Li; An Huang; Lili Guo; Shouyu Wang; Yun Xue; Bing Wu; Lichao Peng; Miaomiao Song; Guodong Li; Shangdong Liang
Journal:  Inflammation       Date:  2015-12       Impact factor: 4.092

3.  Brain changes associated with thromboxane receptor antagonist SQ 29,548 treatment in a mouse model.

Authors:  Andrew A Rebel; Siri A Urquhart; Kendra L Puig; Atreyi Ghatak; Stephen A Brose; Mikhail Y Golovko; Colin K Combs
Journal:  J Neurosci Res       Date:  2015-02-22       Impact factor: 4.164

Review 4.  Neurovascular Coupling in Type 2 Diabetes With Cognitive Decline. A Narrative Review of Neuroimaging Findings and Their Pathophysiological Implications.

Authors:  Mads C J Barloese; Christian Bauer; Esben Thade Petersen; Christian Stevns Hansen; Sten Madsbad; Hartwig Roman Siebner
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-04       Impact factor: 6.055

5.  Impaired Cerebral Autoregulation-A Common Neurovascular Pathway in Diabetes may Play a Critical Role in Diabetes-Related Alzheimer's Disease.

Authors:  Shashank Shekhar; Shaoxun Wang; Paige N Mims; Ezekiel Gonzalez-Fernandez; Chao Zhang; Xiaochen He; Catherine Y Liu; Wenshan Lv; Yangang Wang; Juebin Huang; Fan Fan
Journal:  Curr Res Diabetes Obes J       Date:  2017-06-05

6.  Overweight and obese patients with nickel allergy have a worse metabolic profile compared to weight matched non-allergic individuals.

Authors:  Mikiko Watanabe; Simonetta Masieri; Daniela Costantini; Rossella Tozzi; Francesca De Giorgi; Elena Gangitano; Dario Tuccinardi; Eleonora Poggiogalle; Stefania Mariani; Sabrina Basciani; Elisa Petrangeli; Lucio Gnessi; Carla Lubrano
Journal:  PLoS One       Date:  2018-08-28       Impact factor: 3.240

7.  The Prostaglandin E2 Receptor EP4 Regulates Obesity-Related Inflammation and Insulin Sensitivity.

Authors:  Mika Yasui; Yukinori Tamura; Manabu Minami; Sei Higuchi; Risako Fujikawa; Taichi Ikedo; Manabu Nagata; Hidenori Arai; Toshinori Murayama; Masayuki Yokode
Journal:  PLoS One       Date:  2015-08-26       Impact factor: 3.240

8.  Adamdec1, Ednrb and Ptgs1/Cox1, inflammation genes upregulated in the intestinal mucosa of obese rats, are downregulated by three probiotic strains.

Authors:  Julio Plaza-Díaz; Cándido Robles-Sánchez; Francisco Abadía-Molina; Virginia Morón-Calvente; María José Sáez-Lara; Alfonso Ruiz-Bravo; María Jiménez-Valera; Ángel Gil; Carolina Gómez-Llorente; Luis Fontana
Journal:  Sci Rep       Date:  2017-05-16       Impact factor: 4.379

Review 9.  Rewiring of Lipid Metabolism in Adipose Tissue Macrophages in Obesity: Impact on Insulin Resistance and Type 2 Diabetes.

Authors:  Veronica D Dahik; Eric Frisdal; Wilfried Le Goff
Journal:  Int J Mol Sci       Date:  2020-07-31       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.